Pilot randomized trial for treatment of bacterial vaginosis using in situ forming metronidazole vaginal gel

Journal of Obstetrics and Gynaecology Research

Volumn 37, Issue 7, 2011, Pages 874-881

  Shaaban, Omar M ^a   Fetih, Gihan N ^b   Abdellah, Noura H ^b   Ismail, Saeyd ^b   Ibrahim, Maggie A ^c   Ibrahim, El Sayed A ^b  

^a ASSIUT UNIVERSITY   (Egypt)

^b Faculty of Medicine   (France)

^c Assiut University   (Egypt)

Author keywords

Bacterial vaginosis; in situ gel; metronidazole; thermo sensitive gel

Indexed keywords

METRONIDAZOLE;

ALLOPATHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; LONG TERM CARE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT OUTCOME; VAGINITIS;

ADULT; ANTI-BACTERIAL AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HOT TEMPERATURE; HUMANS; METRONIDAZOLE; PHYSICOCHEMICAL PHENOMENA; PILOT PROJECTS; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINOSIS, BACTERIAL; YOUNG ADULT;

EID: 80052733733     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2010.01457.x     Document Type: Article

References (28)

1. Schmid G, Markowitz L, Joesoef R, Koumans E. Bacterial vaginosis and HIV infection. Sex Transm Infect 2000; 76: 3-4. (Pubitemid 30320986)
2. Koumans EH, Kendrick JS. Preventing adverse sequelae of bacterial vaginosis: a public health program and research agenda. Sex Transm Dis 2001; 28: 292-297. (Pubitemid 32402150)
3. Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL. Anti-microbial resistance associated with the treatment ofbacterial vaginosis. Am J Obstet Gynecol 2004; 191: 1124-1129. (Pubitemid 39421560)
4. Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases. Morb Mort Wkly Rep 1998; 47: 70-79.
5. Brandt M, Abels C, May T, Lohmann K, Schmidts-Winkler I, Hoyme UB. Intravaginally applied metronidazole is as effec-tive as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects. Eur J Obstet Gynecol Reprod Biol 2008; 141: 158-162.
6. Wain AM. Metronidazole vaginal gel 0.75% (MetroGel-Vaginal): a brief review. Infect Dis Obstet Gynecol 1998; 6: 3-7. (Pubitemid 28249207)
7. Livengood CH 3rd, Soper DE, Sheehan KL et al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis. 1999; 26: 137-142.
8. Paavonen J, Mangioni C, Martin MA, Wajszczuk CP. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol 2000; 96: 256-260. (Pubitemid 30447349)
9. Boris J, Pahlson C, Larsson PG. Six years observation after successful treatment of bacterial vaginosis. Infect Dis Obstet Gynecol 1997; 5: 297-302. (Pubitemid 28079670)
10. Hillier S, Holmes K. Bacterial Vaginosis. In: Holmes K et al. (ed.). Sexually Transmitted Diseases. New York: McGraw Hill, 1999; 563-586.
11. Simoes JA, Aroutcheva AA, Shott S, Faro S. Effect of metron-idazole on the growth of vaginal lactobacilli in vitro. Infect Dis Obstet Gynecol 2001; 9: 41-45. (Pubitemid 32510023)
12. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 2000; 50: 27-46. (Pubitemid 30326687)
13. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological char-acteristics. Pharm Res 2006; 23: 2709-2728. (Pubitemid 44885361)
14. Hennink WE, van Nostrum CF. Novel crosslinking methods to design hydrogels. Adv Drug Deliv Rev 2002; 54: 13-36. (Pubitemid 34075312)
15. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002; 54: 3-12. (Pubitemid 34081178)
16. Masteikova R, Chalupova Z, Sklubalova Z. Stimuli-sensitive hydrogels in controlled and sustained drug delivery. Medicina (Kaunas) 2003; 39 (Suppl 2): 19-24.
17. Van Tomme SR, Storm G, Hennink WE. In situ gelling hydro-gels for pharmaceutical and biomedical applications. Int J Pharm 2008; 355: 1-18.
18. Gagne N, Cormier H, Omar RF et al. Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9. Sex Transm Dis 1999; 26: 177-183. (Pubitemid 29122742)
19. Chang JY, Oh YK, Choi HG, Kim YB, Kim CK. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int J Pharm 2002; 241: 155-163. (Pubitemid 34667075)
20. Mandal TK. Swelling-controlled release system for the vaginal delivery ofmiconazole. Eur J Pharm Biopharm 2000; 50: 337-343.
21. Mauck CK, Katz D, Sandefer EP et al. Vaginal distribution of Replens and K-Y Jelly using three imaging techniques. Con-traception 2008; 77: 195-204.
22. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. AmJ Med 1983; 74: 14-22. (Pubitemid 13221599)
23. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29: 297-301.
24. Owen DH, Katz DF. A vaginal fluid simulant. Contraception 1999; 59: 91-95. (Pubitemid 29244754)
25. Abdellah NH. Pharmaceutical studies on formulation of certain topically applied drugs in polymeric gelling systems (Dissertation). Assiut: Assiut University, 2010.
26. Gupta P, Vermani K, Garg S. Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today 2002; 7: 569-579. (Pubitemid 34603648)
27. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 2001; 53: 321-339. (Pubitemid 34024913)
28. Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev 2002; 54: 37-51. (Pubitemid 34075313)